Credit & articulation pathways
2+1, 1+2 and 3+1 structures, credit transfer and recognised entry points — built to satisfy both regulators and academic boards.
We specialise in building and managing partnerships, with our strength in health and life sciences. Whether it is a clinical trial or a wildlife conservation programme, we deliver across.
Introductions are not hard to arrange. What is hard is the year after signing — when the champion moves on, the first cohort underperforms, an approval lapses, or the priorities on one side quietly change. We stay through that. It is why we manage partnerships rather than simply broker them, and why we take on only a few at a time.
There is no single right way to partner across borders. We help you choose the model that fits your goals, your market and your appetite for risk — then build it.
2+1, 1+2 and 3+1 structures, credit transfer and recognised entry points — built to satisfy both regulators and academic boards.
Co-taught, dual and joint programmes with shared curriculum and shared credentials, designed with partner faculty from the start.
Feasibility, regulatory pathway, approvals and launch — then we stay on the ground while the campus finds its feet.
Joint research programmes, translation collaborations and access to the institutes, hospitals and industry parks that make them real.
Placements, live projects, clinical exposure and talent pipelines with hospital groups, pharma, medtech and manufacturers.
Institution-wide and national agreements with ministries, state bodies and public agencies for workforce and capability at scale.
Plenty of people can open a door in India or Southeast Asia. Very few will tell you which door is wrong for you, and fewer still will turn down work that does not fit. We take on a small number of institutions at a time, because that is the only way the strategy stays specific to the one paying for it.
We choose carefully on both sides. A long partner list is not an asset if half of it was never a real fit — and a partnership that should not have been signed costs more than the one you never started.
A plan built for one university and re-sold to the next is the most expensive kind of cheap. Everything we produce is written for a single institution, its appetite for risk and its timeline.
We have sat on your side of these approvals. We know what a faculty can sign off without making a special case of it, and what a pilot has to cost to survive its second year. Working with us should not cost you your budget.
Judge us on the work, what it produced and how it was delivered — not on the size of the firm that produced it.
Humans, animals, plants, microbes and food are governed by the same biological system — and, increasingly, by the same problems. We work across all of it, and we build partnerships across those boundaries rather than within them.
India is culturally, institutionally and industrially diverse. Most institutions approach it with a single lens and wait years for a return. We bring an academic and industry network built over eighteen years, so the time between entering and seeing outcomes gets considerably shorter.
Every engagement follows the same four movements, in the same order. What changes is what has to be solved at each step.
We begin with what you are actually trying to solve — the objective, the constraint and the timeline — before anything is proposed.
A detailed assessment of your organisation’s real capability and standing. Partnerships fail when they are built on what an institution wishes it had.
We match those strengths to the right partner from our network, structure the agreement and take it through to signature.
We stay on it after signing and manage the partnership to the outcome you set — delivery, revenue, reputation or reach.
Every partnership is matched from a network built over eighteen years, not sourced on request.
You set the priority at the outset, and it governs how the partnership is designed and run.
Partnerships need something running inside them. VyUDIE is a health and life sciences technology company whose platforms carry workforce capability, research translation and institutional intelligence across the same areas we work in.
Visit vyudie.com →NexSphere opens and structures the partnership.
VyUDIE is what makes it deliver.
Tell us your goals and the markets you want to reach, and we will come back with the model we would actually recommend.
Founder-led, deliberately small, and accountable to a handful of institutions at a time.
NexSphere builds cross-border partnerships for universities, governments and industry, with our strength in health and life sciences. We do one thing well: we find the right partner, structure the right model, and stay accountable through delivery. What runs inside those partnerships is built by VyUDIE, our technology engine.
The firm is Australian, with an Indian entity and continuous operations across India. Its founding view is simple — the sector has no shortage of advice, and a considerable shortage of people who will stay until something is actually delivered.
I did not arrive at higher education from consulting. I trained as a biotechnologist and then spent nearly two decades inside the Australian university system, in senior international roles across six universities — building research collaboration, industry and government engagement, and institution-to-institution partnerships from the inside rather than from across the table.
That matters for a practical reason. I know what a partnership looks like from the desk that has to deliver it: which approvals are real obstacles and which are formalities, what a faculty will genuinely resource, and why so many agreements quietly stop after the signing photograph. NexSphere exists because I kept watching good partnerships fail at the delivery stage rather than the negotiation.
Vignesh Vijayaraghavan — Founder & Chief Executive Officer
The world is one family. Knowledge, opportunity and capability should move freely across borders — and the best outcomes come from partners working as one.
A growing network across Australia, India, Malaysia, New Zealand, Vietnam and beyond — supporting partnership development, industry engagement and research translation.
University of Tasmania
University of Canterbury
INTI International University
IMU University
Phenikaa University
Gujarat Technological University
Andhra Pradesh MedTech Zone
Ketim Technologies
University of Tasmania
University of Canterbury
INTI International University
IMU University
Phenikaa University
Gujarat Technological University
Andhra Pradesh MedTech Zone
Ketim TechnologiesEngagements are shaped around institutional priorities and may span partnership development, capability building, industry-linked learning, innovation pathways and translational collaboration. Descriptions here are intentionally broad and do not disclose confidential scope or commercial arrangements.
Alongside the founder, two people carry the delivery and the regional relationships.
A biomedical engineer and regulatory specialist who anchors operations and delivery quality, grounding every engagement in rigour and governance.
Leads engagement across Sri Lanka and the Maldives, with long-standing institutional relationships throughout the region.
Tell us what you are trying to achieve and which markets matter, and we will tell you honestly whether we are the right firm for it.
One sector, broad areas and six ways to build inside them. Whether it is a clinical trial or a wildlife conservation programme, the work is the same.
Broad by design. Humans, animals, plants, microbes and food are governed by the same biological system, and the partnerships worth building increasingly cross between them.
Drug development, formulation and pharmaceutical manufacturing.
Devices, diagnostics, biomaterials and clinical technology.
Genomics, bioprocessing and biomanufacturing.
Agri-science, agri-biotechnology and sustainable production.
Food safety, processing, nutrition and supply.
Fisheries, marine biology and marine bioresources.
Biodiversity, ecology, animal health and conservation science.
Medicine, nursing, allied health, public health and policy.
And more. If the work is life sciences, it is within scope — the list above describes where we are strongest, not where we stop.
Antimicrobial resistance does not respect the boundary between an aquaculture pond and a hospital ward. The same sequencing platform reads a pathogen, a patient, a crop and a wild population. Nutrition sits between agriculture and clinical medicine. A biomanufacturing plant does not much care whether the output is a biologic or a protein for food.
We build partnerships across those boundaries rather than within them — which is where the funding, the industry interest and the unclaimed ground currently sit.
There is no single right way to partner across borders. We help you choose the model that fits your goals, your market and your appetite for risk — then build it, and manage it. Each one below sets out exactly what we do inside it.
Articulation, credit transfer and staged pathways such as 2+1, 1+2 and 3+1, which let students earn recognised credit across institutions and borders. We structure the academic mapping, the quality documentation and the student-facing pathway so the arrangement survives contact with both regulators and academic boards.
Co-taught, dual and joint programmes delivered with partner faculty — shared curriculum, shared credentials and a clear split of teaching, assessment and quality responsibility. These arrangements fail on governance far more often than on academic content, so that is where we spend the effort.
Opening an offshore campus is the start, not the finish. We work with you from feasibility and market fit through the regulatory pathway, approvals and launch, and then stay on the ground through operations so the campus performs rather than simply opens.
Joint research programmes, translation collaborations and innovation partnerships across pharmaceutics, biomedical engineering, biotechnology, agriculture, food science, marine science and conservation — with institutions, medtech parks, research councils and industry. We broker and structure the relationship and open the doors; the research itself is delivered through VyUDIE, our technology engine, and its research partners.
Partnerships that connect institutions with employers — placements, live projects, clinical exposure, innovation briefs and graduate pipelines. That means hospital groups, pharmaceutical manufacturers, diagnostics and device firms, food processors, the aquaculture industry and conservation bodies.
Large-scale, institution-wide partnerships with ministries, state governments and public agencies for capacity building, workforce development and skills. These move slowly and reward patience, local presence and a genuine understanding of national priorities.
We do not arrive with a template. We start with your problem statement, assess the strengths, curate the fit and manage it to the outcome you set.
We begin with what you are actually trying to solve — the objective, the constraint and the timeline — before anything is proposed.
A detailed assessment of your organisation’s real capability and standing. Partnerships fail when they are built on what an institution wishes it had.
We match those strengths to the right partner from our network, structure the agreement and take it through to signature.
We stay on it after signing and manage the partnership to the outcome you set — delivery, revenue, reputation or reach.
Every partnership is matched from a network built over eighteen years, not sourced on request.
You set the priority at the outset, and it governs how the partnership is designed and run.
Tell us the problem you are solving and the outcome that matters — delivery, revenue, reputation or reach — and we will tell you what we would build.
India is the most contested market in health and life sciences right now. Attention is not the advantage — knowing precisely where to enter, with whom, and in what order is.
Pharmaceutics, biomedical engineering, biotechnology, agriculture and food, marine science and the health workforce are all being constructed at once — each with its own policy, its own regulator and its own geography. Every serious institution in the world has noticed. You do not need us to tell you the market is large. What is worth knowing is how long we have been working inside it.
Market size, seat numbers and growth forecasts can be found by anyone with an afternoon, and everyone competing for the same partners already has them. What cannot be found is which state to enter for your discipline, which regulator’s current position will decide your approval, which institution will still be a serious partner in five years, and which adjacent area you should be moving on at the same time.
That reading is the work. We do not publish it, because it is what universities engage us to produce — specific to their discipline, their risk appetite and their timeline, not a view broadcast to everyone including their competitors.
Every framework governing health and life sciences partnership in India has been replaced or created inside six years. Which of them bites, and how hard, depends entirely on your discipline and your state.
Medical, allied health, nursing and midwifery, and dental.
UGC regulations opened Indian soil to foreign universities.
A stated push from import dependence to domestic capability.
The first national bioeconomy policy anywhere, spanning health, agriculture and sustainability.
These are standing positions, not projects. They are the reason an engagement with us starts further along than a cold market entry does — and what we build inside them is designed for one university at a time.
India supplies around a fifth of the world’s generic medicines by volume. Its stated ambition is now biologics, biosimilars and advanced therapies — and that is a capability problem before it is a capital problem.
A market moving from roughly US$55 billion toward US$120–130 billion by 2030, with national programmes behind biologics and a CRDMO sector doubling.
This is the sector we know best at both ends — Australian pharmacy and pharmaceutical science faculties on one side, Indian pharmacy institutions, manufacturers and the policy environment on the other.
India imports most of its medical devices while building the capacity to make them. That gap is precisely where translation partnerships belong.
India’s first integrated medical device park runs to 270 acres, houses more than a hundred companies, and offers shared scientific facilities no individual manufacturer could fund alone. A second zone on a larger footprint has been announced.
We hold an advisory role inside that ecosystem. For a university with device or diagnostics research, that is a direct route to testing infrastructure, manufacturing partners and the regulatory people who sit within it — not a cold approach through a trade body.
India is the world’s second-largest fish producer and a top-three producer across much of agriculture. Almost no foreign university partnership is built here.
Fish production has roughly doubled in a decade across an 11,099 km coastline, alongside a food processing sector carrying 13% of national exports and a bioeconomy policy naming climate-resilient agriculture as a priority.
We read this as life sciences rather than as agriculture. A marine biology group, a pharmacy school and a food science department belong in one partnership, and we are among very few people making that argument in this market.
Clinical exposure, placement capacity and workforce programmes rest on relationships inside hospital groups — not on an agreement signed with a university.
823 medical colleges and 5,299 nursing institutions, distributed across the country in a pattern that does not follow reputation. Distribution follows capability rather than reputation, and the two are frequently confused.
We hold an advisory role with one of India’s major private hospital groups and long-standing relationships across hospital and diagnostics networks, alongside nearly two decades in senior international roles across six Australian universities.
Named engagements, the obstacles inside them and the outcomes they produced are discussed in conversation rather than published — partly out of respect for the partners involved, and partly because the approach itself is what we are engaged for. Ask and we will walk you through the most relevant one.
The sequence is the same in every engagement. What changes is what has to be solved at each step.
We begin with what you are actually trying to solve — the objective, the constraint and the timeline — before anything is proposed.
A detailed assessment of your organisation’s real capability and standing. Partnerships fail when they are built on what an institution wishes it had.
We match those strengths to the right partner from our network, structure the agreement and take it through to signature.
We stay on it after signing and manage the partnership to the outcome you set — delivery, revenue, reputation or reach.
Every partnership is matched from a network built over eighteen years, not sourced on request.
You set the priority at the outset, and it governs how the partnership is designed and run.
Tell us the discipline and the scale you are aiming for. The specific read — where to enter, who to approach and in what order — is what we produce for you, and it starts with a conversation.
Whether you are a university, a government body or an industry partner, tell us the sector and what you are trying to achieve, and we will come back to you.
This opens your email app with the message ready to send to ceo@gonexsphere.com.